AI’s impact on healthcare, other industries continues to grow

The use of AI continues to rise throughout the United States, according to a new industry report published by RELX. The report included feedback from more than 1,000 senior-level executives representing seven industries: healthcare, science/medical, government, insurance, legal, banking and agriculture.

Responses included in the second annual “RELX Emerging Tech Executive Report” show just how quickly these technologies are gaining popularity. While 48% of respondents said their businesses were using AI in 2018, for instance, that number jumped to 72% in 2019. And 69% of respondents said they believe AI has a “very or somewhat positive impact” on their industry in 2018—that number is all the way at 93% in 2019.

Other key findings include:

  • 93% of respondents say AI—including machine learning, deep learning and other related technologies—help their business remain competitive
  • 54% of respondents say AI optimizes their systems and reduces cost
  • 64% of respondents say more of their business is “touched” by AI now than one year ago
  • 53% of respondents believe the government should increase its funding and development when it comes to AI

“The survey results highlight the need for American businesses to be agile and flexible in the way they use AI technologies,” Vijay Raghavan, executive director of the chief technology officer forum at RELX, said in a prepared statement. “Emerging technologies have the capabilities to be incredibly powerful tools, enabling businesses to remain competitive and achieve business goals. Companies with AI integration can offer better products and services and those who don’t risk becoming obsolete.” 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.